There are currently 208 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
NCT04314752
Recruiting
The objectives of the proposed study are to develop and evaluate protocols for ethnic/racial minority-specific research using cancer registry data. In conjunction with the Cancer Registry of Greater California (CRGC), the investigators have developed procedures to identify, recruit, and survey ethnic/racial minority patients with MM. To pilot the study, the investigators aim initially to test the feasibility of this protocol by contacting 400 eligible patients (100 African Americans, 100 Latinos... Read More
Gender:
All
Ages:
21 years and above
Trial Updated:
08/30/2023
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Multiple Myeloma
Register for Updates
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
NCT03127761
Recruiting
Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT). Allogeneic HCT (alloHCT) is the only potentially curative therapy available to patients with MM. However, the significant morbidity and mortality of this procedure historically limited its application in older patients. Thus, although potentially curative, standard risk MM patients have e... Read More
Gender:
All
Ages:
All
Trial Updated:
08/29/2023
Locations: Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota
Conditions: Multiple Myeloma
Register for Updates
Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients
NCT04634435
Recruiting
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of cytokine induced memory-like (CIML) NK cells plus KP1237 and low dose IL-2 in newly diagnosed MM patients who have minimal residual disease (MRD+) in first remission prior to autologous stem cell transplant (ASCT).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
08/28/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Multiple Myeloma
Register for Updates
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
08/11/2023
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +727 locations
Conditions: Multiple Myeloma
Register for Updates
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
NCT05908396
Recruiting
This is a first in human, phase 1, multicenter, open-label study to determine the safety and tolerability of IGM-2644 as a single agent in participants with relapsed and/or refractory MM, for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate. Dose escalation and dose expansion cohorts will be enrolled to evaluate safety, preliminary efficacy, and further define a RP2D. The total length of the study, from screening of the first parti... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: City of Hope, Duarte, California +4 locations
Conditions: Multiple Myeloma
Register for Updates
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
NCT05706766
Recruiting
The goal of this research study is to investigate whether a virtual, home-based, prehabilitation aerobic and resistance exercise (PARE) training program implemented 8 weeks prior to receiving autologous stem cell transplant (ASCT) for multiple myeloma participants will improve muscular strength, physical capacity, patient reported outcomes, and cardiometabolic health outcomes. The names of the study interventions involved in this study are: Prehabilitative aerobic and resistance exercise (PARE... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/10/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Multiple Myeloma, Stem Cell Transplant Complications
Register for Updates
Determining Normal Range for Free Light Chains in Serum Among Twins
NCT04191057
Recruiting
The objective of this study is to recruit healthy adult identical and fraternal twins for the collection of one teaspoon of blood to be sent to the Clinical Lab at San Francisco General Hospital. The serum will be tested to determine the reference range for free light chains.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
08/10/2023
Locations: San Francisco General Hospital, San Francisco, California
Conditions: Multiple Myeloma
Register for Updates
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
NCT05974150
Recruiting
The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic patient reported outcome (PRO) surveys are c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/08/2023
Locations: Yale Cancer Center, New Haven, Connecticut +6 locations
Conditions: Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer, Acute Myelogenous Leukemia
Register for Updates
64Cu-LLP2A for Imaging Multiple Myeloma
NCT03804424
Recruiting
The investigators are performing a trial with goals to demonstrate the feasibility of imaging multiple myeloma (MM) patients with 64Cu-LLP2A-positron emission tomography (PET)/magnetic resonance (MR). The investigators suggest that 64Cu-LLP2A will allow for an accurate molecular imaging of MM lesions, which will have an important impact on early stage disease detection and in the long term on the initiation and choice of therapy in these patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/30/2023
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Multiple Myeloma
Register for Updates
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
NCT05469893
Recruiting
The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually do not have symptoms but are at risk for progressing to active multiple myeloma (MM). Multiple Myeloma is a cancer of the plasma cells, which are an important part of the immune system. Patients with active multiple myeloma generally require treatmen... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/30/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
Register for Updates
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
NCT03689595
Recruiting
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
Gender:
All
Ages:
30 years and above
Trial Updated:
07/30/2023
Locations: The Johns Hopkins Hospital, Baltimore, Maryland +2 locations
Conditions: Multiple Myeloma
Register for Updates
Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma
NCT04635189
Recruiting
The purpose of this study is to determine the effects of daratumumab and lenalidomide without steroids for treating patients with multiple myeloma.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
07/17/2023
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Multiple Myeloma
Register for Updates